Price
No data yet.
Social Signal Score
Analyst Ratings
9 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Claire Mazumdar Clemon
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 103
- Beta
- -0.82
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- 14.59
Financials
Net Income
$-55.44MEBITDA
$-54.71MFree Cash Flow
$-44.27MEPS (diluted)
$-0.82Shares Outstanding (diluted)
67.93M+24.4%Operating Expenses
$59.95MCash & Debt
$497.26MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-137.95M | $-2.52 |
| 2024 | $0.00 | $-68.00M | $-1.25 |
| 2023 | $0.00 | $-51.98M | $-1.00 |
| 2022 | $0.00 | $-37.84M | $-0.73 |
Valuation
BCAXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
103-6.82%Social Signal Score
Mentions (4)
- Newsseekingalpha.com·54d ago·Positive
Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds Bicara Therapeutics (BCAX) is upgraded to 'Buy' on favorable early clinical signals for ficerafusp alfa in head and neck cancer. BCAX's phase 1 data show promising median overall survival, but toxicity and small cohort size warrant caution ahead of pivotal phase 3 readout. Strong cash position ($500M liquidity) supports operations into 2029, enabling pursuit of interim phase 3 results and potential commercialization.
View source ↗ - Newsbenzinga.com·55d ago·Negative
Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript Bicara Therapeutics Inc. (BCAX) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·55d ago·Neutral
Bicara Therapeutics Q2 Earnings Call Highlights Bicara Therapeutics NASDAQ: BCAX used its second-quarter 2026 earnings call to outline leadership changes, progress in its pivotal head and neck cancer program and plans to expand development of ficerafusp alfa, or FICERA, while reaffirming its cash runway into the first half of 2029.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.84 per share
Typical surprise -21.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.82 vs $-0.82miss
- Mon, May 11$-0.93 vs $-0.64miss
- Thu, Mar 26$-0.68 vs $-0.72beat
- Mon, Nov 10$-0.67 vs $-0.55miss
- Tue, Aug 12$-0.50 vs $-0.54beat
- Tue, May 13$-0.68 vs $-0.40miss
Estimates and results for BCAX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by BCAX officers and directors.
- Bought
- —
- Sold
- $6.2m
0 trades
34 trades
- Cohlhepp Ryansold
- Cohlhepp Ryansold
- Hyep Ivansold
- Mazumdar Clairesold
- Cohlhepp Ryansold
- Mazumdar Clairesold
- Mazumdar Clairesold
- Cohlhepp Ryansold
66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in BCAX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.